Risk factors for death of patients with cystic fibrosis awaiting lung transplantation

被引:129
作者
Belkin, RA
Henig, NR
Singer, LG
Chaparro, C
Rubenstein, RC
Xie, SX
Yee, JY
Kotloff, RM
Lipson, DA
Bunin, GR
机构
[1] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Pulm, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Allergy, Philadelphia, PA 19104 USA
[3] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Allergy, Philadelphia, PA 19104 USA
[4] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Crit Care, Philadelphia, PA 19104 USA
[5] Univ Penn, Med Ctr, Ctr Clin Epidemiol & Biostat, Div Biostat, Philadelphia, PA 19104 USA
[6] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA
[7] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA
[8] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[9] Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA
[10] Univ Toronto, Div Respirol, Hlth Network, Toronto, ON, Canada
[11] Univ Toronto, Toronto, ON, Canada
关键词
cystic fibrosis; lung transplantation; survival;
D O I
10.1164/rccm.200410-1369OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Rationale: The optimal timing for listing of cystic fibrosis patients for lung transplantation is controversial. Objectives: We conducted a retrospective cohort study of 343 patients listed for lung transplantation at four academic medical centers to identify risk factors for death while awaiting transplantation. Methods: Data on possible risk factors were abstracted from medical records. Measurements: Time to death, patient demographic characteristics, and risk factors for death while awaiting transplantation were assessed. Univariate and multivariate survival analyses were performed using Cox regression. Results: By univariate analyses, FEV1 <= 30% predicted (HR, 3.8; 95% CI, 2.0-7.5), Pa-CO2 >= 50 mm Hg (HR, 1.85; 95% CI, 1.1-3.0), and shorter height (HR, 1.8; 95% Cl, 1.1-3.0) were associated with a higher risk of death. Referral from an accredited cystic fibrosis center was associated with a lower risk (HR, 0.53; 95% Cl, 0.30-0.92). The final multivariate model included referral from an accredited cystic fibrosis center (HR, 0.5; 95% Cl, 0.3-1.0) and listing year after 1996 (HR, 0.4; 95% Cl, 0.2-0.7); both were associated with a lower risk of death. FEV1 <= 0% predicted (HR, 6.8; 95% CI, 2.4-19.3), Pa-CO2 >= 50 mm Hg (HR, 6.9; 95% CI, 1.5-32.1), and use of a nutritional intervention (HR, 2.3; 95% Cl, 1.3-4.1) were associated with increased risk. Patients with FEV1 > 30% predicted had a higher risk of death only when their Pa-CO2 was >= 50 mm Hg (HR, 7.0; 95% Cl, 1.5-32), while the increased risk of death with FEV1 <= 30% was not further influenced by the presence of hypercapnia. Conclusions: We identified risk factors for waiting list mortality that could impact on transplant listing and allocation guidelines.
引用
收藏
页码:659 / 666
页数:8
相关论文
共 44 条
[1]   Medical progress - Lung transplantation [J].
Arcasoy, SM ;
Kotloff, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (14) :1081-1091
[2]   Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients [J].
Augarten, A ;
Akons, H ;
Aviram, M ;
Bentur, L ;
Blau, H ;
Picard, E ;
Rivlin, J ;
Miller, MS ;
Katznelson, D ;
Szeinberg, A ;
Shmilovich, H ;
Paret, G ;
Laufer, J ;
Yahav, Y .
PEDIATRIC TRANSPLANTATION, 2001, 5 (05) :339-342
[3]   Stature as a prognostic factor in cystic fibrosis survival [J].
Beker, LT ;
Russek-Cohen, E ;
Fink, RJ .
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION, 2001, 101 (04) :438-442
[4]  
BELKIN RA, 2001, PEDIAT PULMONOL, V32, P317
[5]  
BELKIN RAB, 2004, PEDIAT PULMONOL S27, V38, P317
[6]   Assessment of survival benefit after lung transplantation by patient diagnosis [J].
Charman, SC ;
Sharples, LD ;
McNeil, KD ;
Wallwork, J .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (02) :226-232
[7]  
COLLETT D, 2003, MODELLING SURVIVAL D, P319
[8]   A COMPARISON OF SURVIVAL, GROWTH, AND PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS IN BOSTON AND TORONTO [J].
COREY, M ;
MCLAUGHLIN, FJ ;
WILLIAMS, M ;
LEVISON, H .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (06) :583-591
[9]   ATS statement: Guidelines for the six-minute walk test [J].
Crapo, RO ;
Casaburi, R ;
Coates, AL ;
Enright, PL ;
MacIntyre, NR ;
McKay, RT ;
Johnson, D ;
Wanger, JS ;
Zeballos, RJ ;
Bittner, V ;
Mottram, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) :111-117
[10]  
Davis PB, 1999, CYSTIC FIBROSIS IN ADULTS, P45